LIPITOR has been studied in more than 400 ongoing or completed studies.

Research on LIPITOR

As the #1 prescribed branded cholesterol-lowering medication in the world, over 29 million people in the United States have been prescribed LIPITOR.1

LIPITOR has been studied in more than 400 ongoing or completed studies. These studies include over 80,000 patients.2

  • A landmark study found that LIPITOR reduced the risk of heart attack, stroke, certain kinds of heart surgeries, and chest pain in patients with several common risk factors for heart disease. Risk factors include family history of early heart disease, high blood pressure, age, low HDL ("good" cholesterol), or smoking
  • Another landmark study found that LIPITOR significantly reduces the risk of heart attack and stroke in patients with both type 2 diabetes and at least 1 other risk factor* for heart disease

Ask your doctor today if LIPITOR is right for you.

*Other risk factors include eye problem, kidney problem, smoking, or high blood pressure.

References:

  1. IMS Health. IMS National Prescription Audit Plus. March 2008.
  2. Data on file. Pfizer Inc, New York, NY.